{"entity":{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","aka":["CSPC","石药集团","CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd."],"tldr":"CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.","summary":"Domestic leader in nanoparticle albumin-bound paclitaxel (Keaili) and pegylated liposomal doxorubicin (Duomeisu); innovative pipeline includes the Nectin-4 ADC SYS6002, the Claudin 18.2 ADC SYSA1801, an EGFR ADC and a PD-1 x VEGF programme; licences include an AI-enabled discovery collaboration with AstraZeneca (June 2025) and ADC deals. Illustrates the shift of China's big generic houses into originator research.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/CSPC_Pharmaceutical_Group","links":[{"label":"Official website","url":"https://www.cspc.com.hk/"}],"tags":["china"],"related":[],"cancers":[],"sections":["chemotherapy","adcs","targeted-therapy"],"technologies":[],"targets":[],"drugs":["paclitaxel","pegylated-liposomal-doxorubicin","sys6010","hb1801","jskn003","kn026","jmt101","farletuzumab-exatecan","sys6023","jmt203"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06313086","nct07714668","nct07254585","nct05427383","nct07280832","nct07165886","nct07122063","nct07415863","nct06957379","nct06877650","nct06947291","nct07597629","nct06505395","nct07744763","nct04668690","nct06391944","nct06296706","nct07241936"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shijiazhuang","country":"CN","companyType":"pharma","website":"https://www.cspc.com.hk/","ticker":"1093.HK","founded":1997,"investors":[],"funding":[]},"route":"/companies/cspc/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/"},{"id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/"},{"id":"jmt101","kind":"drug","name":"JMT101","route":"/drugs/jmt101/"},{"id":"jmt203","kind":"drug","name":"JMT203","route":"/drugs/jmt203/"},{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/"},{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"},{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/"},{"id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06296706","kind":"trial","name":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","route":"/trials/nct06296706/"},{"id":"nct06735391","kind":"trial","name":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","route":"/trials/nct06735391/"},{"id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/"},{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/"},{"id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/"},{"id":"nct07750041","kind":"trial","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07750041/"},{"id":"nct07376382","kind":"trial","name":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","route":"/trials/nct07376382/"},{"id":"nct06747338","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","route":"/trials/nct06747338/"},{"id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","route":"/trials/nct07441460/"},{"id":"nct06868849","kind":"trial","name":"A Study of JMT203 in Patients With Cancer Cachexia","route":"/trials/nct06868849/"},{"id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","route":"/trials/nct07241936/"},{"id":"nct07256509","kind":"trial","name":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No","route":"/trials/nct07256509/"},{"id":"nct07672223","kind":"trial","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07672223/"},{"id":"nct06829459","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","route":"/trials/nct06829459/"},{"id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/"},{"id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/"},{"id":"nct07122063","kind":"trial","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","route":"/trials/nct07122063/"},{"id":"nct06313086","kind":"trial","name":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","route":"/trials/nct06313086/"},{"id":"nct05838066","kind":"trial","name":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct05838066/"},{"id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/"},{"id":"nct06391944","kind":"trial","name":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","route":"/trials/nct06391944/"},{"id":"nct06846437","kind":"trial","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","route":"/trials/nct06846437/"},{"id":"nct05427383","kind":"trial","name":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","route":"/trials/nct05427383/"},{"id":"nct06571461","kind":"trial","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","route":"/trials/nct06571461/"},{"id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","route":"/trials/nct07415863/"},{"id":"nct07280832","kind":"trial","name":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","route":"/trials/nct07280832/"},{"id":"nct06927986","kind":"trial","name":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","route":"/trials/nct06927986/"},{"id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/"},{"id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","route":"/trials/nct07165886/"},{"id":"nct06957379","kind":"trial","name":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","route":"/trials/nct06957379/"},{"id":"nct07254585","kind":"trial","name":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","route":"/trials/nct07254585/"},{"id":"nct07633873","kind":"trial","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","route":"/trials/nct07633873/"},{"id":"nct07442565","kind":"trial","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","route":"/trials/nct07442565/"}]}}